Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Gynecology

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 44 articles:
HTML format



Single Articles


    November 2021
  1. BYUN D, Hong S, Ryu S, Nam Y, et al
    Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose-response meta-analysis of prospective studies.
    Br J Cancer. 2021 Nov 12. pii: 10.1038/s41416-021-01625.
    PubMed     Abstract available


  2. GUFFANTI F, Alvisi MF, Anastasia A, Ricci F, et al
    Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    Br J Cancer. 2021 Nov 3. pii: 10.1038/s41416-021-01609.
    PubMed     Abstract available


    October 2021
  3. MURPHY AD, Morgan RD, Clamp AR, Jayson GC, et al
    The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
    Br J Cancer. 2021 Oct 29. pii: 10.1038/s41416-021-01605.
    PubMed     Abstract available


  4. BLACKFORD AL, Childs EJ, Porter N, Petersen GM, et al
    A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO.
    Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01580.
    PubMed     Abstract available


  5. SI S, Li J, Tewara MA, Li H, et al
    Identifying causality, genetic correlation, priority and pathways of large-scale complex exposures of breast and ovarian cancers.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01576.
    PubMed     Abstract available


  6. XIE SH, Santoni G, Lagergren J
    Menopausal hormone therapy and risk of oesophageal adenocarcinoma in a population-based cohort study.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01575.
    PubMed     Abstract available


    September 2021
  7. IDEN M, Tsaih SW, Huang YW, Liu P, et al
    Multi-omics mapping of human papillomavirus integration sites illuminates novel cervical cancer target genes.
    Br J Cancer. 2021 Sep 15. pii: 10.1038/s41416-021-01545.
    PubMed     Abstract available


    August 2021
  8. MULLEE A, Dimou N, Allen N, O'Mara T, et al
    Testosterone, sex hormone-binding globulin, insulin-like growth factor-1 and endometrial cancer risk: observational and Mendelian randomization analyses.
    Br J Cancer. 2021 Aug 6. pii: 10.1038/s41416-021-01518.
    PubMed     Abstract available


    June 2021
  9. FENG JL, Dixon-Suen SC, Jordan SJ, Webb PM, et al
    Statin use and survival among women with ovarian cancer: an Australian national data-linkage study.
    Br J Cancer. 2021 Jun 16. pii: 10.1038/s41416-021-01460.
    PubMed     Abstract available


    May 2021
  10. XU X, Wang Y, Bryce NS, Tang K, et al
    Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents.
    Br J Cancer. 2021 May 12. pii: 10.1038/s41416-021-01420.
    PubMed     Abstract available


    April 2021
  11. TIN TIN S, Reeves GK, Key TJ
    Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank.
    Br J Cancer. 2021 Apr 16. pii: 10.1038/s41416-021-01392.
    PubMed     Abstract available


  12. BIZZARRI N, Pedone Anchora L, Zannoni GF, Carbone V, et al
    Validation of tumour-free distance as novel prognostic marker in early-stage cervical cancer: a retrospective, single-centre, cohort study.
    Br J Cancer. 2021 Apr 14. pii: 10.1038/s41416-021-01384.
    PubMed     Abstract available


  13. KREGTING LM, Kaljouw S, de Jonge L, Jansen EEL, et al
    Effects of cancer screening restart strategies after COVID-19 disruption.
    Br J Cancer. 2021;124:1516-1523.
    PubMed     Abstract available


    March 2021
  14. LEPAGE CC, Palmer MCL, Farrell AC, Neudorf NM, et al
    Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer.
    Br J Cancer. 2021 Mar 17. pii: 10.1038/s41416-021-01317.
    PubMed     Abstract available


  15. ZHANG X, Ling MT, Feng H, Wong YC, et al
    Retraction Note to: Id-1 stimulates cell proliferation through activation of EGFR in ovarian cancer cells.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01322.
    PubMed    


  16. ARTHUR RS, Dannenberg AJ, Kim M, Rohan TE, et al
    The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-020-01210.
    PubMed     Abstract available


  17. SARINK D, Wilkens LR, White KK, Le Marchand L, et al
    Racial/ethnic differences in anthropometric and hormone-related factors and endometrial cancer risk: the Multiethnic Cohort Study.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01292.
    PubMed     Abstract available


  18. HALLE MK, Sodal M, Forsse D, Engerud H, et al
    A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01305.
    PubMed     Abstract available


  19. EINBOND LS, Zhou J, Wu HA, Mbazor E, et al
    A novel cancer preventative botanical mixture, TriCurin, inhibits viral transcripts and the growth of W12 cervical cells harbouring extrachromosomal or integrated HPV16 DNA.
    Br J Cancer. 2021;124:901-913.
    PubMed     Abstract available


    February 2021
  20. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available


  21. CASTANON A, Rebolj M, Pesola F, Sasieni P, et al
    Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01275.
    PubMed     Abstract available


  22. HAYASHI T, Konishi I
    Correlation of anti-tumour drug resistance with epigenetic regulation.
    Br J Cancer. 2021;124:681-682.
    PubMed     Abstract available


  23. LITWIN TR, Irvin SR, Chornock RL, Sahasrabuddhe VV, et al
    Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis.
    Br J Cancer. 2021;124:831-841.
    PubMed     Abstract available


    January 2021
  24. SESTAK I, Blake G, Patel R, Cuzick J, et al
    Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial.
    Br J Cancer. 2021 Jan 22. pii: 10.1038/s41416-020-01228.
    PubMed     Abstract available


  25. LU H, Cunnea P, Nixon K, Rinne N, et al
    Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer.
    Br J Cancer. 2021 Jan 21. pii: 10.1038/s41416-020-01252.
    PubMed     Abstract available


  26. BRAGA A, Elias KM, Horowitz NS, Berkowitz RS, et al
    When less is more: regarding the use of chest X-ray instead of computed tomography in screening for pulmonary metastasis in postmolar gestational trophoblastic neoplasia.
    Br J Cancer. 2021 Jan 8. pii: 10.1038/s41416-020-01209.
    PubMed     Abstract available


  27. SALAS-BENITO D, Conde E, Tamayo-Uria I, Mancheno U, et al
    The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1(+) tumour-infiltrating lymphocytes.
    Br J Cancer. 2021 Jan 5. pii: 10.1038/s41416-020-01218.
    PubMed     Abstract available


  28. WINFIELD JM, Wakefield JC, Brenton JD, AbdulJabbar K, et al
    Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis.
    Br J Cancer. 2021 Jan 4. pii: 10.1038/s41416-020-01217.
    PubMed     Abstract available


    December 2020
  29. PARKER VL, Winter MC, Whitby E, Parker WAE, et al
    Computed tomography chest imaging offers no advantage over chest X-ray in the initial assessment of gestational trophoblastic neoplasia.
    Br J Cancer. 2020 Dec 16. pii: 10.1038/s41416-020-01206.
    PubMed     Abstract available


  30. CIBULA D, Slama J, Dostalek L, Fischerova D, et al
    Tumour-free distance: a novel prognostic marker in patients with early-stage cervical cancer treated by primary surgery.
    Br J Cancer. 2020 Dec 14. pii: 10.1038/s41416-020-01204.
    PubMed     Abstract available


  31. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available


    November 2020
  32. KAMAL M, Lameiras S, Deloger M, Morel A, et al
    Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site.
    Br J Cancer. 2020 Nov 16. pii: 10.1038/s41416-020-01153.
    PubMed     Abstract available


  33. YAN S, Xuan J, Brajanovski N, Tancock MRC, et al
    The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
    Br J Cancer. 2020 Nov 11. pii: 10.1038/s41416-020-01158.
    PubMed     Abstract available


  34. LI YY, Gao LJ, Zhang YX, Liu SJ, et al
    Bisphosphonates and risk of cancers: a systematic review and meta-analysis.
    Br J Cancer. 2020;123:1570-1581.
    PubMed     Abstract available


    October 2020
  35. MILLINGTON K, Hayes K, Pilcher S, Roberts S, et al
    A serous borderline ovarian tumour in a transgender male adolescent.
    Br J Cancer. 2020 Oct 27. pii: 10.1038/s41416-020-01129.
    PubMed     Abstract available


  36. ZHANG Y, Yu M, Jing Y, Cheng J, et al
    Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer.
    Br J Cancer. 2020 Oct 22. pii: 10.1038/s41416-020-01123.
    PubMed     Abstract available


  37. ARROYO MUHR LS, Lagheden C, Lei J, Eklund C, et al
    Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR.
    Br J Cancer. 2020 Oct 6. pii: 10.1038/s41416-020-01111.
    PubMed     Abstract available


    September 2020
  38. KIM HS, Park SY, Park CY, Kim YT, et al
    A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer.
    Br J Cancer. 2020 Sep 30. pii: 10.1038/s41416-020-01098.
    PubMed     Abstract available


  39. MO XT, Leung TH, Tang HW, Siu MK, et al
    CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma.
    Br J Cancer. 2020;123:833-843.
    PubMed     Abstract available


    August 2020
  40. KYRGIOU M, Arbyn M, Bergeron C, Bosch FX, et al
    Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC).
    Br J Cancer. 2020;123:510-517.
    PubMed     Abstract available


    July 2020
  41. METCALFE KA, Price MA, Mansfield C, Hallett DC, et al
    Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis.
    Br J Cancer. 2020;123:268-274.
    PubMed     Abstract available


    May 2020
  42. LEI J, Ploner A, Lehtinen M, Sparen P, et al
    Impact of HPV vaccination on cervical screening performance: a population-based cohort study.
    Br J Cancer. 2020 May 4. pii: 10.1038/s41416-020-0850.
    PubMed     Abstract available


    April 2020
  43. ARBYN M, Rezhake R, Yuill S, Canfell K, et al
    Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence.
    Br J Cancer. 2020 Apr 3. pii: 10.1038/s41416-020-0787.
    PubMed     Abstract available


    February 2020
  44. ROBERTS C, Strauss VY, Kopijasz S, Gourley C, et al
    Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
    Br J Cancer. 2020;122:483-490.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: